Vyvanse / Elvanse Duration Curve & Afternoon Crash: What to Log
Why the Vyvanse and Elvanse afternoon crash happens, how to separate it from normal tiredness, and what to track during titration so your prescriber can adjust dose or timing.
Get new titration guides by email
Occasional, evidence-based guides on medication tracking and titration — no noise.
Disclaimer: This article is for educational purposes only. It does not constitute medical advice, diagnosis, or a prescription recommendation. All medication decisions must be made by you and your licensed healthcare provider based on your individual medical history and circumstances.
Vyvanse (US) and Elvanse (UK and Israel) are the same medication: lisdexamfetamine, an amphetamine prodrug. It is one of the longest-acting ADHD stimulants, with a smoother pharmacokinetic curve than most immediate-release and extended-release alternatives. For many adults, it produces a single daily dose that covers the full workday and a less abrupt wear-off than short-acting formulations.
But Vyvanse/Elvanse is not crash-proof. The afternoon decline — a gradual return of ADHD symptoms, lower energy, irritability, or a sudden appetite surge — is one of the most commonly reported experiences. This guide explains the duration curve, what the afternoon crash actually is, how to tell it from normal tiredness, and what to log so your prescriber can act on it.
What is Vyvanse / Elvanse?
Lisdexamfetamine is a prodrug: the capsule contains an inactive molecule (lisdexamfetamine dimesylate) that must be converted by enzymes in red blood cells into the active drug, dextroamphetamine. This conversion happens gradually, which is why Vyvanse has a slow onset and a long, flat effect profile [1].
Because the active drug is released through enzymatic conversion rather than a mechanical pump, Vyvanse's curve is less "peaky" than many other stimulants. This makes it popular for adults who get anxious or jittery on IR formulations.
Brand names by market
| Market | Brand name | Notes |
|---|---|---|
| United States | Vyvanse | 10 mg, 20 mg, 30 mg, 40 mg, 50 mg, 60 mg, 70 mg capsules; also chewable tablets |
| UK / Ireland | Elvanse | Same molecule, different branding |
| Israel | Elvanse | Common long-acting amphetamine option alongside Concerta |
| Other markets | Tyvense, Venvanse | Same active ingredient |
Israeli adults often search for both Vyvanse and Elvanse in English, even though the local brand is Elvanse. This guide uses both names interchangeably.
Vyvanse / Elvanse dosing and titration
The standard adult starting dose is 30 mg once daily, with typical weekly increases of 10–20 mg until a therapeutic dose is reached. The licensed maximum in most markets is 70 mg/day [2].
| Week | Typical adult dose | Notes |
|---|---|---|
| Week 1 | 30 mg once daily | Starting dose; checks tolerability |
| Week 2 | 40–50 mg once daily | Many adults start noticing clear benefit here |
| Week 3 | 50–60 mg once daily | Common target range |
| Week 4+ | 60–70 mg if needed | Maximum licensed dose; only if lower doses are insufficient |
Some prescribers use 20 mg as a starting dose for adults who are very sensitive to stimulants. Children and adolescents have different weight-based dosing.
The Vyvanse / Elvanse duration curve
Vyvanse does not peak sharply. Most adults describe the experience as a gradual ramp-up, a long plateau, and a gradual decline. The full clinical effect is usually described as 10–12 hours, though some people feel residual effects for 14 hours or longer [3].
| Time after dose | Phase | Typical experience |
|---|---|---|
| 0–1.5 hours | Onset | Subtle; some people feel nothing yet |
| 1.5–4 hours | Rising effect | Focus and motivation improve |
| 4–8 hours | Peak / plateau | Strongest symptom control |
| 8–12 hours | Gradual decline | Effect tapers; some notice rebound |
| 12+ hours | Wear-off | ADHD symptoms return; sleep risk if dose was late |
Because the conversion is enzyme-dependent, the onset is slower than with swallowed XR medications. Taking it on a full stomach does not change total absorption much but can delay the onset by 30–60 minutes. The most important practical rule is consistency: take it the same way each day so your curve stays predictable.
What is the afternoon crash?
The "afternoon crash" on Vyvanse/Elvanse is usually one of two things — and telling them apart changes the treatment plan.
1. Pharmacokinetic decline (the real medication wear-off)
As lisdexamfetamine is converted and cleared, the brain's dopamine and norepinephrine levels gradually fall. For some adults, this decline produces a noticeable dip in focus, energy, or mood 8–12 hours after dosing. This is a rebound-like return of ADHD symptoms as coverage drops.
Common signs:
- Return of distractibility and impulsivity
- Lower energy, mental fatigue
- Irritability or emotional sensitivity
- Sudden appetite increase
- Difficulty completing evening tasks
2. Normal circadian dip amplified by stimulant timing
The human body has a natural afternoon circadian dip around 2–4 PM. Stimulants can mask this dip early in the day and then make the contrast feel sharper when coverage falls. This may not be a "crash" at all — it may be the normal afternoon slump that the medication had been suppressing.
The difference matters because the fixes are different: a true rebound may need a dose adjustment or booster, while a normal circadian dip may respond to a short walk, a snack, a nap, or task-scheduling changes.
What to log during Vyvanse / Elvanse titration
Logging is the only way to separate a real medication issue from a normal day. During the first 3–4 weeks, track at least these three time points:
| Time after dose | What to log |
|---|---|
| 1.5 hours | Focus, motivation, any anxiety or jitteriness |
| 4–6 hours | Peak effect, productivity, appetite, mood |
| 8–12 hours | Afternoon decline, rebound symptoms, mood, sleep readiness |
At each point, rate:
- Focus (1–5)
- Energy/motivation (1–5)
- Irritability or anxiety (1–5)
- Appetite (1–5)
Also log:
- Dose time — consistency matters
- Food — did you take it with or without food?
- Sleep — time to fall asleep, total hours, quality
- Caffeine — amount and timing (caffeine + amphetamine increases cardiovascular load)
Patterns that matter for your prescriber
The data is only useful if it reveals patterns. These are the patterns that most often lead to a dosing change:
| Pattern | Likely meaning | Common prescriber response |
|---|---|---|
| Strong effect 2–4 hours, then sharp decline by 8 hours | Fast metabolism or dose too low | Increase dose or consider alternative |
| Flat all day, then sudden crash at 10–12 hours | Normal wear-off at end of duration | Earlier dosing, or discuss booster if clinically appropriate |
| Anxiety/jitteriness at 2–4 hours, then flat | Dose too high or onset too fast | Lower dose or consider prodrug/alternative |
| Good effect, but sleep onset delayed 2+ hours | Dose too late or too high | Earlier dose time, lower dose, or formulation change |
| Appetite suppression severe all day | Dose-related or too high | Lower dose, nutritional strategies, or alternative |
| Afternoon crash only on days with poor sleep | Sleep is the driver, not the dose | Address sleep hygiene or sleep disorder first |
Managing the afternoon crash without changing your dose
Before your prescriber changes the medication, there are timing and lifestyle adjustments that can help:
- Take your dose earlier — if the wear-off is happening at 8 PM, an earlier dose time may move the rebound earlier and protect sleep.
- Eat a protein-rich breakfast — protein stabilizes energy and can smooth the rebound window.
- Hydrate throughout the day — dehydration worsens fatigue and headache on stimulants.
- Plan low-demand tasks for the decline phase — don't schedule difficult conversations or complex decisions for 8–10 hours after dosing.
- Limit caffeine — caffeine + amphetamine worsens the cardiovascular and anxiety load.
- Track for 2–3 weeks — patterns are more reliable than single-day impressions.
When to ask about a dose or formulation change
Talk to your prescriber if:
- The afternoon crash is functionally impairing (you can't parent, work, or drive safely)
- The crash is getting worse as you increase the dose
- You need coverage beyond 12 hours
- Sleep onset is consistently delayed by 2+ hours
- Anxiety or irritability during the peak is significant
- Appetite suppression is affecting nutrition or weight
Possible prescriber responses include: dose adjustment, timing adjustment, switching to a different formulation, adding a small IR booster, or switching to a non-stimulant adjunct.
Track your Vyvanse / Elvanse curve with Titrate
The afternoon crash is one of the most under-reported parts of ADHD stimulant treatment because it happens after the workday, when most people aren't thinking about their medication. But it's often the most important signal for whether the dose, timing, or formulation is right.
Titrate makes this easy: daily check-ins at the times that matter, a structured effect curve, and a shareable report that shows your prescriber exactly when your coverage rises, peaks, and falls — not just what you remember from the morning of your appointment.
→ Start tracking your Vyvanse / Elvanse curve free ← → See how prescribers view Titrate reports ←
Also see our guides on Concerta titration and stimulant titration timelines.
FAQ
Q: How long does Vyvanse / Elvanse last? Most adults experience 10–12 hours of clinical effect. Some feel residual effects for 14 hours, while others metabolize faster and feel a shorter window. Enzyme activity, body weight, sleep, and food can all influence duration.
Q: Can I take Vyvanse / Elvanse later on weekends? It's generally better to keep the time consistent. Taking it even 2 hours later can push the wear-off into bedtime and disrupt sleep. If you sleep in, consider taking it immediately on waking or skipping the day with your prescriber's guidance.
Q: Does food change how Vyvanse / Elvanse works? Food doesn't change total absorption much but can delay onset by 30–60 minutes. The key is consistency — take it the same way each day so your curve is predictable.
Q: Is the afternoon crash a sign the dose is too low? Not necessarily. A crash can mean the dose is too low, too high, or simply that the medication is wearing off at the end of its normal duration. Logging the timing and severity of the crash is what helps your prescriber decide.
Q: Can I take a second dose of Vyvanse / Elvanse in the afternoon? No, unless your prescriber specifically prescribed a booster. Vyvanse/Elvanse is designed as a once-daily medication. A second dose can cause insomnia, cardiovascular effects, and other risks. Some prescribers add a different short-acting booster if needed.
Q: Why does Vyvanse feel smoother than Adderall XR? Vyvanse is a prodrug converted by enzymes in the blood, which creates a slower, more consistent rise in active drug. Adderall XR uses a dual-bead system that can produce a more biphasic curve. Individual response varies.
Q: Is generic Vyvanse the same as brand-name? Generic lisdexamfetamine must meet bioequivalence standards, but some patients report differences in effect onset or duration. If you notice a change after a pharmacy switch, log it and tell your prescriber.
Key takeaways
- Vyvanse and Elvanse are the same medication — lisdexamfetamine — with different brand names in different markets.
- The prodrug design produces a smoother, longer curve than many other stimulants, with a gradual onset and 10–12 hour effect.
- The "afternoon crash" is often a mix of medication wear-off and normal circadian dip — logging tells them apart.
- Track at 1.5 hours, 4–6 hours, and 8–12 hours after dosing to see your full curve.
- Timing, food, caffeine, and sleep all affect the curve — consistency makes the data useful.
- A crash that impairs evening function is a clinical signal — not something to ignore.
- Titrate turns daily logging into a shareable report your prescriber can use to adjust dose or timing.
References
- Vyvanse (lisdexamfetamine dimesylate) — FDA Prescribing Information. Available at: https://www.accessdata.fda.gov/drugsatfda_docs/label/2017/021977s082lbl.pdf
- NICE Guideline NG87 — Attention deficit hyperactivity disorder: diagnosis and management (2018, updated 2019).
- Pennick M. Absorption of lisdexamfetamine dimesylate and its enzymatic conversion to d-amphetamine. Neuropsychiatr Dis Treat. 2010;6:317-327.
- Faraone SV, et al. The pharmacology of amphetamine and methylphenidate: relevance to the neurobiology of ADHD. Biol Psychiatry. 2006;59(11):1086-1090.
- Cortese S, et al. Comparative efficacy and tolerability of medications for ADHD: a systematic review and network meta-analysis. Lancet Psychiatry. 2018;5(9):727–738.
This article is for educational purposes only. It does not constitute medical advice. Always consult your licensed healthcare provider about medication decisions.